Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daclatasvir + sofosbuvir + ribavirin for 12 versus 16 weeks in genotype 3 chronic hepatitis C with advanced fibrosis or compensated cirrhosis
2014-005310-28Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jun 2015
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of daclatasvir, sofosbuvir and ribavirin in hepatitis C virus infection (2 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Sustained virologic response at 12 weeks after treatment (SVR12). Started Jun 2015; status: completed.
02
Drugs
daclatasvirsofosbuvirribavirin
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on 2014-005310-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005310-28.